E Alefishat1, S P H Alexander, V Ralevic. 1. Cardiovascular Research Group and Lipid Signalling, School of Biomedical Sciences, University of Nottingham, Nottingham, UK.
Abstract
BACKGROUND AND PURPOSE: Acyl derivatives of CoA have been shown to act as antagonists at human platelet and recombinant P2Y1 receptors, but little is known about their effects in the cardiovascular system. This study evaluated the effect of these endogenous nucleotide derivatives at P2Y1 receptors natively expressed in rat and porcine blood vessels. EXPERIMENTAL APPROACH: Isometric tension recordings were used to evaluate the effects of CoA, acetyl CoA, palmitoyl CoA (PaCoA) and 3'-dephospho-palmitoyl-CoA on concentration relaxation-response curves to ADP and uridine triphosphate (UTP). A FlexStation monitored ADP- and UTP-evoked calcium responses in HEK293 cells. KEY RESULTS: Acetyl CoA and PaCoA, but not CoA, inhibited endothelium-dependent relaxations to ADP with apparent selectivity for P2Y1 receptors (over P2Y(2/4) receptors) in rat thoracic aorta; PaCoA was more potent than acetyl CoA (331-fold vs. fivefold shift of ADP response curve evoked by 10 μM PaCoA and acetyl CoA, respectively); the apparent pA2 value for PaCoA was 6.44. 3'-dephospho-palmitoyl-CoA (10 μM) was significantly less potent than PaCoA (20-fold shift). In porcine mesenteric arteries, PaCoA and the P2Y1 receptor antagonist MRS2500 blocked ADP-mediated endothelium-dependent relaxations; in contrast, they were ineffective against ADP-mediated endothelium-independent relaxation in porcine coronary arteries (which does not involve P2Y1 receptors). Calcium responses evoked by ADP activation of endogenous P2Y1 receptors in HEK293 cells were inhibited in the presence of PaCoA, which failed to alter responses to UTP (acting at endogenous P2Y(2/4) receptors). CONCLUSIONS AND IMPLICATIONS: Acyl derivatives of CoA can act as endogenous selective antagonists of P2Y1 receptors in blood vessels, and this inhibitory effect critically depends on the palmitate and 3'-ribose phosphate substituents on CoA.
BACKGROUND AND PURPOSE: Acyl derivatives of CoA have been shown to act as antagonists at human platelet and recombinant P2Y1 receptors, but little is known about their effects in the cardiovascular system. This study evaluated the effect of these endogenous nucleotide derivatives at P2Y1 receptors natively expressed in rat and porcine blood vessels. EXPERIMENTAL APPROACH: Isometric tension recordings were used to evaluate the effects of CoA, acetyl CoA, palmitoyl CoA (PaCoA) and 3'-dephospho-palmitoyl-CoA on concentration relaxation-response curves to ADP and uridine triphosphate (UTP). A FlexStation monitored ADP- and UTP-evoked calcium responses in HEK293 cells. KEY RESULTS:Acetyl CoA and PaCoA, but not CoA, inhibited endothelium-dependent relaxations to ADP with apparent selectivity for P2Y1 receptors (over P2Y(2/4) receptors) in rat thoracic aorta; PaCoA was more potent than acetyl CoA (331-fold vs. fivefold shift of ADP response curve evoked by 10 μM PaCoA and acetyl CoA, respectively); the apparent pA2 value for PaCoA was 6.44. 3'-dephospho-palmitoyl-CoA (10 μM) was significantly less potent than PaCoA (20-fold shift). In porcine mesenteric arteries, PaCoA and the P2Y1 receptor antagonist MRS2500 blocked ADP-mediated endothelium-dependent relaxations; in contrast, they were ineffective against ADP-mediated endothelium-independent relaxation in porcine coronary arteries (which does not involve P2Y1 receptors). Calcium responses evoked by ADP activation of endogenous P2Y1 receptors in HEK293 cells were inhibited in the presence of PaCoA, which failed to alter responses to UTP (acting at endogenous P2Y(2/4) receptors). CONCLUSIONS AND IMPLICATIONS: Acyl derivatives of CoA can act as endogenous selective antagonists of P2Y1 receptors in blood vessels, and this inhibitory effect critically depends on the palmitate and 3'-ribose phosphate substituents on CoA.
Authors: Pieter-Jan D F Guns; András Korda; Herta M Crauwels; Tim Van Assche; Bernard Robaye; Jean-Marie Boeynaems; Hidde Bult Journal: Br J Pharmacol Date: 2005-09 Impact factor: 8.739
Authors: Pieter-Jan D F Guns; Tim Van Assche; Paul Fransen; Bernard Robaye; Jean-Marie Boeynaems; Hidde Bult Journal: Br J Pharmacol Date: 2006-03 Impact factor: 8.739
Authors: Michael T Wunderlich; Thorsten Hanhoff; Michael Goertler; Friedrich Spener; Jane F C Glatz; Claus-W Wallesch; Maurice M A L Pelsers Journal: J Neurol Date: 2005-04-18 Impact factor: 4.849
Authors: Claudio Coddou; Gloria Loyola; José Luis Boyer; Miguel Bronfman; J Pablo Huidobro-Toro Journal: FEBS Lett Date: 2003-02-11 Impact factor: 4.124
Authors: Friedhelm Schroeder; Anca D Petrescu; Huan Huang; Barbara P Atshaves; Avery L McIntosh; Gregory G Martin; Heather A Hostetler; Aude Vespa; Danilo Landrock; Kerstin K Landrock; H Ross Payne; Ann B Kier Journal: Lipids Date: 2007-09-19 Impact factor: 1.880
Authors: Hak Sung Kim; Michihiro Ohno; Bin Xu; Hea Ok Kim; Yongseok Choi; Xiao D Ji; Savitri Maddileti; Victor E Marquez; T Kendall Harden; Kenneth A Jacobson Journal: J Med Chem Date: 2003-11-06 Impact factor: 7.446
Authors: Song-Young Park; Matthew J Rossman; Jayson R Gifford; Leena P Bharath; Johann Bauersachs; Russell S Richardson; E Dale Abel; J David Symons; Christian Riehle Journal: Am J Physiol Heart Circ Physiol Date: 2016-01-29 Impact factor: 4.733